尿激酶溶栓治疗急性心肌梗死临床分析

Clinical Analysis of Urokinase Thrombolysis Treatment of Acute Myocardial Infarction

目的探讨尿激酶溶栓在急性心肌梗死中的治疗效果。方法选取2012-11—2015-03就诊于新疆阿克苏地区第一人民医院CCU急性心肌梗死患者81例,按是否溶栓将患者分为对照组42例和尿激酶组39例,对照组按急性心肌梗死常规治疗,尿激酶组在常规治疗基础上,采用尿激酶溶栓治疗。尿激酶组中按发病至溶栓时间分为6h之内溶栓组25例和6-12h内溶栓组14例。分别比较对照组与尿激酶组、6h之内溶栓组和6-12h内溶栓组的冠脉再通率。结果尿激酶组的冠脉再通率为54%,明显高于对照组的12%,两组差异有统计学意义(X^2=16.31,p<0.05);尿激酶组中,发病至溶栓时间6h之内的冠脉再通率为68%,明显高于发病至溶栓时间6-12h内的29%,两组差异有统计学意义(X^2=5.61,p<0.05)。结论尿激酶溶栓是早期急性心肌梗死有效的治疗方法,发病至溶栓时间越早,冠脉再通率越高,值得临床推广。

Objective To investigate the therapeutic effect of urokinase thrombolysis in acute myocardial infarction. Methods 81 cases of acute myocardial infarction patients treated at CCU of the hospital from November 2012 to march 2015 were enrolled, all the patients were divided into two groups according to whether thrombolysis： the control group 42 cases and the urokinase group 39 eases, the control group using conventional treatment of acute myocardial infarction, the urokinase group using urokinase thrombolysis treatment on the basis of conventional treatment. All the patients of Urokinase group were divided into two groups according to the time of onset to thrombolysis： 25 cases of the thrombolysis group within Six hours, six to twelve hours thrombolysis group in 14 cases. Compared with the control group and the urokinase group, thrombolysis group within Six hours and six to twelve hours thrombolysis group of coronary reperfusion rate. Resdts Coronary reperfusion rate of the urokinase group （54%） was significantly higher than that of the control group （12%）, the differences between the two groups was statistically significant （X^2 =16.31, p 〈0.05）; in the urokinase group,Coronary reperfusion rate of thrombolysis group within Six hours（68%） was signifieantly higher than that of the six to twelve hours thrombolysis group （29%）, the differences between the two groups was statistically significant （X^2 =5.61, p 〈0.05）. Conclusion Urokinase thrombolytie therapy is an effective treatment for early acute myocardial infarction, the earlier the onset to thrombolysis, the higher the coronary reperfusion rate, it is worthy for clinical promotion.